Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Claudin 18.2 and its role in advanced gastric cancers
Claudin 18.2 (CLDN18.2) is a tight junction protein predominantly found in gastric epithelial cells. In gastric cancers, its expression becomes aberrant, making it a promising...
Accelerated approval is granted by FDA to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as...
Capmatinib is approved for metastatic non-small cell lung cancer
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as...
Darolutamide tablets is approved by FDA for metastatic hormone-sensitive prostate cancer
August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-sensitive...
Fam-trastuzumab deruxtecan-nxki is approved by FDA for HER2-low breast cancer
August 2022: For adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH) breast cancer who have received prior chemotherapy in the metastatic setting...
Crizotinib is approved by FDA for ALK-positive inflammatory myofibroblastic tumor
July 2022: Crizotinib (Xalkori, Pfizer Inc.) was granted approval by the Food and Drug Administration (FDA) for the treatment of adult and paediatric patients 1...
A memorandum of understanding (MOU) has been signed by GenScript ProBio to form a strategic partnership with ACT Therapeutics to develop new CAR-T cell therapies
July 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor...
CAR T-Cell therapy market will grow at phenomenal rate in next 8 years
July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion...
Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug
June 2022: According to the findings of a study that was just recently published by Stanford Medicine in mice, a cancer treatment that makes use of...
New CAR T-cell therapy showed acceptable safety profile in solid tumors
April 2022: According to preliminary data from a phase I/II clinical trial that was presented during the AACR Annual Meeting 2022, which was held from April...
Korean homegrown CAR T-Cell therapy is on the way
Nov 2021: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals,...
Lisocabtagene maraleucel is approved by FDA for second-line treatment of large B-cell lymphoma
July 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large B-cell lymphoma (LBCL) who...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.